Reference number : GC-2017-Q4-00648, amendment number : , agreement type : G, recipient legal name : Gauthier, Marc (Institut national de la recherche scientifique), recipient country : CA, recipient province : nan, recipient city : Quebec|Québec, recipient postal code : nan, program name english : Engage Grants for universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : For a medication to be effective, it must be able to reach its target. One of the greatest challenges for many_x000D_
drugs is that their targets lie inside cells. Indeed, cells are surrounded by a membrane that keeps many_x000D_
molecules out - including drugs. Even the most powerful drug will be ineffective if it cannot reach its target._x000D_
Feldan Therapeutics Inc. has developed a technology, termed the Feldan shuttle, which facilitates the transfer_x000D_
of several types of drugs into cells. They now face a technological challenge, associated with the stability of the_x000D_
Shuttle in blood, that they cannot resolve themselves. As such, Feldan Therapeutics Inc. has approached Prof_x000D_
Marc A Gauthier of the INRS to investigate structural alterations to the Shuttle and the influence of these_x000D_
modifications on: 1) the physical nature of complexes formed with therapeutic cargo, and 2) their interaction_x000D_
with blood proteins., program purpose french : For a medication to be effective, it must be able to reach its target. One of the greatest challenges for many_x000D_
drugs is that their targets lie inside cells. Indeed, cells are surrounded by a membrane that keeps many_x000D_
molecules out - including drugs. Even the most powerful drug will be ineffective if it cannot reach its target._x000D_
Feldan Therapeutics Inc. has developed a technology, termed the Feldan shuttle, which facilitates the transfer_x000D_
of several types of drugs into cells. They now face a technological challenge, associated with the stability of the_x000D_
Shuttle in blood, that they cannot resolve themselves. As such, Feldan Therapeutics Inc. has approached Prof_x000D_
Marc A Gauthier of the INRS to investigate structural alterations to the Shuttle and the influence of these_x000D_
modifications on: 1) the physical nature of complexes formed with therapeutic cargo, and 2) their interaction_x000D_
with blood proteins., agreement title english : Polymer conjugation to the Feldan Shuttle to reduce blood protein adsorption and interaction with cell membranes, agreement title french : Polymer conjugation to the Feldan Shuttle to reduce blood protein adsorption and interaction with cell membranes, agreement number : EGP, agreement value : 25000.0, agreement start date : 2018-03-07, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada